Patients with cryptogenic stroke treated with routine transcatheter patent foramen ovale closure have increased 4-year stroke risk.

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

About Virtue SAB Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver a proprietary, ...